<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264573</url>
  </required_header>
  <id_info>
    <org_study_id>MSCs, PRP, Scar</org_study_id>
    <nct_id>NCT03264573</nct_id>
  </id_info>
  <brief_title>Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars</brief_title>
  <official_title>Role of Stem Cells, Platelet Rich Plasma and Combination of Them in Treatment of Scars</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heba Mohamed Saad Eldien</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.A. Eloteify</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ahmed Kamal Osman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>G.M. Hafsa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Objectives of this randomized controlled trial aiming to establishing a protocol of post
      scar revision care and to Study the effect of PRP and/or Adipose derived Mesenchymal Stem
      cell injection in improvement of atrophic scar after scar revision.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty patients with atrophic scar since one to five years including 25 males and 15 females
      with ages ranging from ten to 35 years with main age of 22.68 will be divided into four
      groups each included ten patients. One group will be treated with scar revision only (control
      group or group I), 2nd group will be injected with PRP after scar revision, 3rd group will be
      injected with ADSCs after scar revision and the 4th group will be injected with a combination
      of PRP and ADSCs after scar revision. All groups were assisted pre-operative and six months
      post-operative. Complications, Scar width, Vancouver scar scale (VSS), surgeon assessment
      scar scale and patient assessment scar scale will be considered the outcome measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction (Patient Assessment Scar Scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Patient Assessment Scar Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Doctor satisfaction (Vancouver Scar Scale)</measure>
    <time_frame>6 months</time_frame>
    <description>Vancouver Scar Scale (VSS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atrophic Scar</condition>
  <arm_group>
    <arm_group_label>stem cell, PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adipose derived MSCs, versus Platelet rich plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem cell, Stem cell and PRP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem cell</intervention_name>
    <description>after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells</description>
    <arm_group_label>stem cell, PRP</arm_group_label>
    <arm_group_label>Stem cell, Stem cell and PRP</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MSCs</intervention_name>
    <description>manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells</description>
    <arm_group_label>stem cell, PRP</arm_group_label>
    <arm_group_label>Stem cell, Stem cell and PRP</arm_group_label>
    <other_name>Stem cell and PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with atrophic scar.

          -  Age group: 5 years up to 35 years.

          -  No previous medications, surgeries or laser therapy.

        Exclusion Criteria:

          -  Patient with hypertrophic or pigmented scar.

          -  Patient with any blood disease.

          -  Patients with lipodystrophy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Heba Mohamed Saad Eldien</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Atrophic scar</keyword>
  <keyword>PRP</keyword>
  <keyword>ADSCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

